8:00 AM GMT, Nov 9, 2009
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact email@example.com.
Leaping for Leptin
More than a decade of unimpressive data had dampened enthusiasm for leptin as an obesity therapeutic when Amylin Pharmaceuticals Inc. acquired rights to the protein from Amgen Inc. in 2006. Three years and two trials later, Amylin has data on a combination therapy approach with a leptin analog that gives the company the chance to monetize its investment.
Under a deal announced last week, the biotech will receive $75 million up front from Takeda Pharmaceutical Co. Ltd.
Read the full 761 word article